Oxford Nanopore Technologies, a UK-based developer of human genome technology, has raised £25m ($41m) from a consortium including its DNA sequencing marketing partner, Illumina UK.

The other investors in Oxford Nanopore, which is valued in the round at £155m, included hedge fund Lansdowne Partners, London-listed developer of intellectual property-based businesses IP Group, mutual fund manager Invesco Perpetual and venture capital firm Redmile Group.

IP Group said its 21.5% beneficial stake in Oxford Nanopore was valued at £33.4m after…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?